Video

PSMA-Based Imaging and Theranostics: A Summary of Current Paradigm Shifts and a Look to the Future

Author(s):

Phillip Koo, MD,Michael S. Cookson, MD, MMHC

The panel discusses the possibility of PSMA-PET becoming the standard-of-care imaging modality for prostate cancer, which may obviate the need for conventional imaging and bone scans, and then touches on the increasing availability of PSMA-targeted radiotherapies.

Related Videos
Jaspreet S. Sandhu, MD, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Michael Jenson, PA-C, answers a question during a Zoom video interview
Couple talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
Health-related QOL is comparable among ARPI regimens for CSPC
January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke
At 25 weeks, FACT-P total score remained comparable between the arms.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
FDA accepts NDA for 3-month leuprolide mesylate formulation for advanced prostate cancer
January 13th 2025

FDA accepts NDA for 3-month leuprolide mesylate formulation for advanced prostate cancer

Hannah Clarke
The PDUFA target action date has been set for August 29, 2025.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Expanded indication sought for darolutamide in mHSPC in China
January 7th 2025

Expanded indication sought for darolutamide in mHSPC in China

Hannah Clarke
The application is supported by data from the pivotal phase 3 ARANOTE trial.
FDA logo
January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely
Catch up on all the notable drug and device approvals in urology over the past year.
© 2025 MJH Life Sciences

All rights reserved.